Athira Pharma Stock Analysis

Athira Stock Analysis Notes

About 62.0% of the company shares are held by institutions such as insurance companies. The company has price-to-book (P/B) ratio of 0.44. Some equities with similar Price to Book (P/B) outperform the market in the long run. Athira Pharma recorded a loss per share of 2.84. The entity had not issued any dividends in recent years. Athira Pharma, Inc., a late clinical-stage biopharmaceutical company, focuses on developing small molecules to restore neuronal health and slow neurodegradation. The company was incorporated in 2011 and is headquartered in Bothell, Washington. Athira Pharma operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 34 people. For more info on Athira Pharma please contact Dr MBA at 425 620 8501 or go to https://www.athira.com.

Athira Pharma Investment Alerts

Athira Pharma Upcoming and Recent Events

Athira Largest EPS Surprises

View All Earnings Estimates

Athira Stock Institutional Investors

Note, although Athira Pharma's institutional investors appear to be way more sophisticated than retail investors, it remains unclear if professional active investment managers can reliably enhance risk-adjusted returns by an amount that exceeds fees and expenses.

Athira Market Capitalization

The company currently falls under 'Micro-Cap' category with a current market capitalization of 25.25 M.

Athira Profitablity

Management Efficiency

Athira Pharma has return on total asset (ROA) of (0.4753) % which means that it has lost $0.4753 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.8457) %, meaning that it created substantial loss on money invested by shareholders. Athira Pharma's management efficiency ratios could be used to measure how well Athira Pharma manages its routine affairs as well as how well it operates its assets and liabilities. As of November 29, 2024, Return On Tangible Assets is expected to decline to -0.77. In addition to that, Return On Capital Employed is expected to decline to -1. At present, Athira Pharma's Total Assets are projected to increase significantly based on the last few years of reporting. The current year's Non Currrent Assets Other is expected to grow to about 1.1 M, whereas Net Tangible Assets are forecasted to decline to about 175.1 M.

Technical Drivers

As of the 29th of November, Athira Pharma shows the mean deviation of 5.86, and Risk Adjusted Performance of (0.06). Athira Pharma technical analysis gives you the methodology to make use of historical prices and volume patterns to determine a pattern that approximates the direction of the firm's future prices.

Athira Pharma Price Movement Analysis

Athira Pharma Insider Trading Activities

Athira Pharma Outstanding Bonds

Athira Pharma Predictive Daily Indicators

Athira Pharma Forecast Models

Athira Pharma's time-series forecasting models are one of many Athira Pharma's stock analysis techniques aimed at predicting future share value based on previously observed values. Time-series forecasting models ae widely used for non-stationary data. Non-stationary data are called the data whose statistical properties e.g. the mean and standard deviation are not constant over time but instead, these metrics vary over time. These non-stationary Athira Pharma's historical data is usually called time-series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the market movement and maximize returns from investment trading.

Stock analysis is the technique used by a trader or investor to examine and evaluate how Athira Pharma prices is reacting to, or reflecting on a current market direction and economic conditions. It can be used to make informed decisions about market timing, and when buying or selling Athira shares will generate the highest return on investment. We also built our stock analysis module to help investors to gain an insight into the world economy as a whole, the stock market, thematic ideas. a specific sector, or an individual Stock such as Athira Pharma. By using and applying Athira Stock analysis, traders can create a robust methodology for identifying Athira entry and exit points for their positions.

We track the performance of the top 100 financial experts across various large and mid-size financial boutiques. Athira analyst recommendations are determined by taking all analyst recommendations and averaging them as Strong Buy, Buy, Hold, Strong Sell or Sell. There is no one specific way to measure analysis performance other than comparing it to the past results via a very sophisticated attribution analysis. Athira analyst consensus and target price projections should be used in combination with other traditional techniques such as stock price forecasting, technical analysis, earnings estimate, and various momentum models.

Athira Pharma stock analysis indicators help investors evaluate how Athira Pharma stock reacts to ongoing and evolving market conditions. The investors can use it to make informed decisions about market timing and determine when trading Athira Pharma shares will generate the highest return on investment. By understating and applying Athira Pharma stock analysis, traders can identify Athira Pharma position entry and exit signals to maximize returns.

When running Athira Pharma's price analysis, check to measure Athira Pharma's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Athira Pharma is operating at the current time. Most of Athira Pharma's value examination focuses on studying past and present price action to predict the probability of Athira Pharma's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Athira Pharma's price. Additionally, you may evaluate how the addition of Athira Pharma to your portfolios can decrease your overall portfolio volatility.